Puma Biotechnology (NASDAQ:PBYI - Get Free Report) is scheduled to be announcing its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of $0.31 per share for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.
Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. Puma Biotechnology had a return on equity of 18.36% and a net margin of 4.01%. The firm had revenue of $47.10 million during the quarter, compared to analyst estimates of $43.99 million. During the same period last year, the firm posted $0.05 EPS. On average, analysts expect Puma Biotechnology to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Puma Biotechnology Stock Performance
NASDAQ:PBYI traded up $0.05 during trading hours on Thursday, reaching $2.89. The stock had a trading volume of 129,374 shares, compared to its average volume of 452,152. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.23 and a current ratio of 1.32. The stock has a market cap of $141.75 million, a P/E ratio of 14.68 and a beta of 1.09. Puma Biotechnology has a 12-month low of $2.22 and a 12-month high of $7.73. The stock has a 50 day simple moving average of $2.61 and a 200 day simple moving average of $3.42.
Insider Activity
In related news, Director Michael Patrick Miller sold 23,358 shares of the business's stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $3.49, for a total transaction of $81,519.42. Following the completion of the transaction, the director now owns 47,000 shares of the company's stock, valued at approximately $164,030. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 23.70% of the company's stock.
Wall Street Analysts Forecast Growth
PBYI has been the subject of several analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 price objective on shares of Puma Biotechnology in a report on Friday, August 2nd. StockNews.com raised Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a report on Wednesday, October 23rd.
View Our Latest Research Report on PBYI
Puma Biotechnology Company Profile
(
Get Free Report)
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Featured Articles
Before you consider Puma Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Puma Biotechnology wasn't on the list.
While Puma Biotechnology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
